BioInvent International AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BINV.ST research report →
Companywww.bioinvent.com
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 in solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma.
- CEO
- Martin Welschof
- IPO
- 2001
- Employees
- 118
- HQ
- Lund, SE
Price Chart
Valuation
- Market Cap
- $1.69B
- P/E
- -5.04
- P/S
- 7.75
- P/B
- 3.85
- EV/EBITDA
- -4.10
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 98.48%
- Op Margin
- -161.05%
- Net Margin
- -153.98%
- ROE
- -53.88%
- ROIC
- -78.78%
Growth & Income
- Revenue
- $226.50M · 406.86%
- Net Income
- $-332,858,000 · 22.48%
- EPS
- $-5.06 · 22.51%
- Op Income
- $-351,391,000
- FCF YoY
- 34.70%
Performance & Tape
- 52W High
- $41.60
- 52W Low
- $19.22
- 50D MA
- $22.65
- 200D MA
- $27.52
- Beta
- -0.05
- Avg Volume
- 119.87K
Get TickerSpark's AI analysis on BINV.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our BINV.ST Coverage
We haven't published any research on BINV.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BINV.ST Report →